EUVIMEDEUVIMED entdecken
BeobachtungsstudieMultizentrische Studie

Efficacy of Vaccination and Revaccination Against Hepatitis B Virus Using 2 Different Strategies in Patients With Inflammatory Bowel Disease

Panagiotis Markopoulos iD, Konstantinos Karmiris iD, Ioannis Dimas, Evangelos Voudoukis, Spyridon Siakavellas, Georgios Axiaris, Eirini Zacharopoulou, Evanthia Zampeli, Eftychia Tsironi, Maria Tzouvala, Georgios Papatheodoridis, Georgios Bamias

Inflammatory Bowel Diseases · 2025

DOI: 10.1093/ibd/izae173 ↗

Kurz gefasst

Beobachtungsstudie in der Zeitschrift Inflammatory Bowel Diseases, 2025. Verfasst von Panagiotis Markopoulos und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gastroenterology, Metaxa Memorial Cancer Hospital, Piraeus, Greece. Hauptthemen laut MEDLINE: Hepatitis B Vaccines, Hepatitis B, Immunization, Secondary, Inflammatory Bowel Diseases. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 36 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Patients with inflammatory bowel disease (IBD) exhibit an increased risk for acquiring hepatitis B virus (HBV), thus they should be vaccinated preferably, if not already infected or immunized. We assessed the efficacy of HBV vaccination in IBD patients and impact of different factors on the immune response. We also evaluated the success rate of 2 different revaccination strategies in the nonresponders.

Methods

This was a retrospective observational cohort study carried out in 5 tertiary centers. All patients were tested for hepatitis B surface antigen, antibodies against hepatitis B surface antigen (anti-HBs), and antibodies against hepatitis B core antigen. Patients tested negative and underwent the standard schedule with 20 µg at 0, 1, and 6 months. Nonresponders (anti-HBs <10 IU/L) were offered a revaccination scheme with either 3 doses of 40 µg at 0, 1, and 6 months or an accelerated scheme with 20 µg at 0, 1, and 2 months.

Results

A total of 409 patients were included, and 273 (66.7%) of those (females: 49.5%; Crohn’s disease [CD]: 56.7%) responded to baseline vaccination. A total of 189 (69.2%) of 273 (females: 48.1%; CD: 60.3%) developed anti-HBs >100 IU/L. Body mass index <30 kg/m2 (P = .017) was positively associated, while diagnosis of CD (P = .013), extensive UC (P <.0001), extraintestinal manifestations (P = .001), and treatment with immunomodulators/anti-tumor necrosis factor (P < .00) negatively affected the response. Revaccination was offered to 103 patients, and 58.3% of them achieved anti-HBs >10 IU/L. Both revaccination strategies were equally effective.

Conclusions

IBD patients demonstrate lower response to HBV vaccination compared with the general population. Age, body mass index, type, disease activity, and immunosuppression negatively affect the response. Half of nonresponders may benefit from an enhanced revaccination attempt.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Hepatitis B VaccinesHepatitis BImmunization, SecondaryInflammatory Bowel DiseasesHepatitis B virusVaccinationHumansMaleFemaleRetrospective StudiesAdultMiddle AgedHepatitis B AntibodiesHepatitis B Surface AntigensYoung AdultFollow-Up Studies

Stichwörter der Autor:innen

Crohn’s diseasehepatitis Bimmune responseinflammatory bowel diseaseulcerative colitisvaccination

Substanzen

Hepatitis B VaccinesHepatitis B AntibodiesHepatitis B Surface Antigens

Autor:innen und Institutionen

  • Department of Gastroenterology, Metaxa Memorial Cancer Hospital, Piraeus, Greece.
  • Department of Gastroenterology, Venizeleio General Hospital, Heraklion, Greece.
  • Department of Gastroenterology, General Hospital of Athens LAIKO, Medical School of National and Kapodistrian University of Athens, Athens, Greece.
  • Department of Gastroenterology, Alexandra General Hospital, Athens, Greece.
  • Department of Gastroenterology, Agios Panteleimon General Hospital, Nikaia, Piraeus - Agia Varvara General Hospital of Western Attica, Athens, Greece.
  • GI Unit, 3rd Department of Internal Medicine, Sotiria General Hospital, Medical School of National and Kapodistrian University of Athens, Athens, Greece.

ORCID-Profile: Panagiotis Markopoulos, Konstantinos Karmiris

Zitieren

APA

Markopoulos, P., Karmiris, K., Dimas, I., Voudoukis, E., Siakavellas, S., Axiaris, G., Zacharopoulou, E., Zampeli, E., Tsironi, E., Tzouvala, M., Papatheodoridis, G., & Bamias, G. (2025). Efficacy of Vaccination and Revaccination Against Hepatitis B Virus Using 2 Different Strategies in Patients With Inflammatory Bowel Disease. Inflammatory Bowel Diseases. https://doi.org/10.1093/ibd/izae173

Vancouver

Markopoulos P, Karmiris K, Dimas I, Voudoukis E, Siakavellas S, Axiaris G, et al. Efficacy of Vaccination and Revaccination Against Hepatitis B Virus Using 2 Different Strategies in Patients With Inflammatory Bowel Disease. Inflammatory Bowel Diseases. 2025. doi:10.1093/ibd/izae173

BibTeX
@article{Markopoulos2025,
  author = {Markopoulos, Panagiotis and Karmiris, Konstantinos and Dimas, Ioannis and Voudoukis, Evangelos and Siakavellas, Spyridon and Axiaris, Georgios and Zacharopoulou, Eirini and Zampeli, Evanthia and Tsironi, Eftychia and Tzouvala, Maria and Papatheodoridis, Georgios and Bamias, Georgios},
  title = {Efficacy of Vaccination and Revaccination Against Hepatitis B Virus Using 2 Different Strategies in Patients With Inflammatory Bowel Disease},
  journal = {Inflammatory Bowel Diseases},
  year = {2025},
  doi = {10.1093/ibd/izae173}
}
Kostenlos starten →